In the latest trading session, Gilead Sciences (GILD) closed at $105.93, marking a -1.18% move from the previous day. Meanwhile, the Dow lost 0.25%, and the Nasdaq, a tech-heavy index, added 0.31%.

Gilead Sciences Inc. closed 11.70% below its 52-week high of $119.96, which the company achieved on March 10th.

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...

Gilead Sciences (NASDAQ:GILD) and Kymera Therapeutics (NASDAQ:KYMR) announced an exclusive partnership on Wednesday to ...

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

Gilead Sciences Inc. and Kymera Therapeutics Inc. have entered into an exclusive option and license agreement.

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...

The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

Both Barad and his co-panelist, Joydeep Ganguly, SVP of corporate operations at Gilead Sciences, emphasized that they see AI ...

The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an ...